What was the primary goal of the quality improvement initiative described for bispecific antibodies in lymphoma treatment?
To compare efficacy of bispecifics versus chemotherapy in community settings
To define how community oncologists are using bispecifics, identify barriers, and help practices develop confidence in implementation
To establish new toxicity management guidelines for academic centers